Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:
Pricing Debate Prescription To Otc Switch Government Payers

HHS Regulatory Agenda Omits Drug Pricing Actions – Unless OTC Switches Still Count

  • Analysis

Executive Summary

HHS’ 'statement of regulatory priorities' for 2018 does not even offer lip service to idea of addressing Rx costs. It does, however, suggest plans to move forward with an effort to increase OTC switches – which was an Obama era idea to lower drug costs.

Table

View full table

Advertisement

Related Content

Pink Sheet
Rulemaking For OTC Switch Process Changes Pushed To 2019
HBW Insight
Rulemaking For OTC Switch Process Changes Pushed To 2019
Pink Sheet
340B Penny Pricing, Civil Monetary Penalty Revisions On Deck In Proposed Rule

Topics

Advertisement
Tags:
Pricing Debate Prescription To Otc Switch Government Payers
UsernamePublicRestriction

Register

PS122194

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By